Madurai News

Polycythemia Vera Market Size and Share Analysis, Clinical Developmental Activities, Key Growth Factors, Leading Companies, Emerging Therapies, and Epidemiology Forecast

 Breaking News
  • No posts were found

Polycythemia Vera Market Size and Share Analysis, Clinical Developmental Activities, Key Growth Factors, Leading Companies, Emerging Therapies, and Epidemiology Forecast

August 11
04:04 2021
Polycythemia Vera Market Size and Share Analysis, Clinical Developmental Activities, Key Growth Factors, Leading Companies, Emerging Therapies, and Epidemiology Forecast
Delveinsight Business Research LLP
DelveInsight’s “Polycythemia Vera Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Polycythemia Vera Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Polycythemia Vera Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Polycythemia Vera market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Polycythemia Vera treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Polycythemia Vera Therapeutic Market

Polycythemia Vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis) and affected people may also have excess white blood cells and platelets. Most cases of PV are not inherited and are acquired during a person’s lifetime.

The most precarious symptom of polycythemia vera is the chance for a thrombotic event that can cause a heart attack or stroke. There is also a small chance that polycythemia vera could cause an individual to develop leukemia. With proper treatment, however, these symptoms have not been shown to greatly affect the expected lifespan of a person with polycythemia vera. 

Polycythemia Vera Market Key Facts

  • According to DelveInsight, the total prevalent population of polycythemia vera (PV) in the 7MM was found to be 296,000 in 2020.

  • Most of the prevalence of Polycythemia Vera was found in the United States with 166,230 cases in 2020.

  • Among the European 5 countries, Germany had the highest symptomatic prevalent population of Polycythemia Vera with 14,778 cases, followed by France and the United Kingdom, in 2020. On the other hand, Spain had the lowest symptomatic prevalent population of 7,663 in 2020.

  • Japan had 19,476 symptomatic prevalent cases for Polycythemia Vera in 2020.

  • A higher percentage of symptomatic prevalence was observed for males, in comparison to females, in all the 7MM countries.

  • Approximately 92,876 cases of Polycythemia Vera were calculated for patients with JAK2 V617F, thereby accounting for the highest number of cases with gene mutation with 97% of total PV cases with JAK2 mutation in the United States.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/polycythemia-vera-market

Key Benefits of Polycythemia Vera Market Report

  • The market report provides an in-depth analysis of Polycythemia Vera Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Polycythemia Vera Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Polycythemia Vera current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Polycythemia Vera market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Polycythemia Vera Therapeutic Market Assessment 

As per the DelveInsight, the therapeutic market of Polycythemia Vera in the seven major markets was assessed to be USD 1,480.08 Million in 2020 and is expected to grow during the study period (2018–2030). Among EU Countries, Germany accounted for the largest market size of PV in 2020, followed by France and the United Kingdom. In contrast, Spain had the smallest market size of PV.

Polycythemia Vera Market 

The Polycythemia Vera market size is expected to increase at a significant CAGR during the study period owing to the launch of emerging therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Polycythemia Vera market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Polycythemia Vera market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request for Sample @ Polycythemia Vera Therapeutics Market Assessment

Polycythemia Vera Epidemiology

The epidemiology section covers insights about the historical and current Polycythemia Vera patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Polycythemia Vera Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycythemia Vera market or expected to get launched in the market during the study period. The analysis covers Polycythemia Vera market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Polycythemia Vera Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Globally, some of the key companies are involved in the development of therapies for the Polycythemia Vera, the therapies are under different stages of development and are expected to launch in the coming years. 

Key Companies in the Polycythemia Vera Market Includes:

  • Italfarmaco 

  • Imago BioSciences 

  • Protagonist Therapeutics 

And others 

Polycythemia Vera Therapies covered in the report includes:

  • PTG-300

  • Givinostat; ITF2357

  • Bomedemstat/IMG-7289

And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Polycythemia Vera Competitive Intelligence Analysis

4. Polycythemia Vera Market Overview at a Glance

5. Polycythemia Vera Disease Background and Overview

6. Polycythemia Vera Patient Journey

7. Polycythemia Vera Epidemiology and Patient Population

8. Polycythemia Vera Treatment Algorithm, Current Treatment, and Medical Practices

9. Polycythemia Vera Unmet Needs

10. Key Endpoints of Polycythemia Vera Treatment

11. Polycythemia Vera Marketed Products

12. Polycythemia Vera Emerging Therapies

13. Polycythemia Vera Seven Major Market Analysis

14. Attribute Analysis

15. Polycythemia Vera Market Outlook (7 major markets)

16. Polycythemia Vera Access and Reimbursement Overview

17. KOL Views on the Polycythemia Vera Market.

18. Polycythemia Vera Market Drivers

19. Polycythemia Vera Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/polycythemia-vera-market

Latest Reports By DelveInsight

Polycythemia Vera Pipeline Insights

Polycythemia Vera Pipeline Insights, 2021 report by DelveInsight outlays detailed insights of present clinical development scenario and growth prospects across Polycythemia Vera Market.

Primary Immune Deficiency (PID) Market

DelveInsight’s “Primary Immune Deficiency (PID) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Primary Immune Deficiency (PID) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/